TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23497667
Drug: Polypharmacy and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy and certain drug classes (thiazides, antidepressants, benzodiazepines, anticonvulsants)
Study: 23497731
Drug: Aerobic exercise
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerobic exercise training (12-week program with a minimum requirement of 17.5 kcal/kg weekly energy expenditure)
Study: 23500218
Drug: iFRa (iFR
Approvals — FDA: no, EMA: no, PMDA: no
Description: iFRa (iFR during adenosine administration)
Study: 23500322
Drug: Daily monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily monitoring of B-type natriuretic peptide (BNP) levels for 60 days with a finger-stick test.
Study: 23504398
Drug: Decitabine at
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine at 45 mg/m² IV over 2 hours on day 1 and 15 and panitumumab 6 mg/kg IV over 1 hour on day 8 and 22 every 28 days
Study: 23504398
Drug: Decitabine and
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine and panitumumab combination
Study: 23506243
Drug: Raltegravir 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 800 mg qd, Atazanavir 600 mg qd, Lamivudine or Emtricitabine
Study: 23506243
Drug: Raltegravir 400
Normalized name: raltegravir 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir 400 mg bid, Atazanavir 600 mg qd, Lamivudine or Emtricitabine
Study: 23511678
Drug: Oxygen administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen administration via nasal cannula at 5 L/min starting 15 minutes after SGB
Study: 23512637
Drug: EE 30
Normalized name: DAYSEE 30MCG/0.15MG EC TAB 91
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 30 μg/LNG 150 μg qd plus empagliflozin 25 mg qd for 7 days (test; period 2)
Study: 23512637
Drug: EE 30
Normalized name: DAYSEE 30MCG/0.15MG EC TAB 91
Approvals — FDA: no, EMA: no, PMDA: no
Description: EE 30 μg/LNG 150 μg qd for 14 days (reference; period 1)
Study: 23512837
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin A (BoNT-A) injection
Study: 23514360
Drug: Everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus 10 mg daily until objective tumor progression, unacceptable toxicity, death, or study discontinuation.
Study: 23516391
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing of foretinib (240 mg/day for 5 days every 2 weeks)
Study: 23516391
Drug: Daily dosing
Normalized name: Osmolex 322 MG Daily Dosing Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily dosing of foretinib (80 mg/day)
Study: 23516391
Drug: Intermittent dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent dosing of foretinib (240 mg/day)
Study: 23516391
Drug: Foretinib treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foretinib treatment
Study: 23516440
Drug: Telmisartan 40
Normalized name: telmisartan 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 40 mg po daily for 24 weeks
Study: 23517449
Drug: Intradermal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intradermal insulin delivery using a hollow microneedle
Study: 23517449
Drug: Subcutaneous insulin
Normalized name: subcutaneous insulin pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous insulin delivery via insulin pump catheter
Study: 23518189
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccine (initial dose)
Study: 23519018
Drug: TCR-engineered ACT
Normalized name: acellular tissue engineered vessel
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCR-engineered ACT immunotherapy
Study: 23520311
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg clarithromycin once daily
Study: 23520311
Drug: 250 mg
Normalized name: rutin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg clarithromycin once daily
Study: 23525441
Drug: Cholesterol absorption
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholesterol absorption markers
Study: 23525751
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for acute ACL tear, specific intervention details not available.
Study: 23529375
Drug: Bevacizumab in
Normalized name: bevacizumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab in combination with radiotherapy and temozolomide
Study: 23530013
Drug: RYGB surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: RYGB surgery with daily matched diet (postsurgery period)
Study: 23530572
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with 5-FU derivatives (specific regimens not detailed)
Study: 23530663
Drug: Ganetespib (STA-9090)
Normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganetespib (STA-9090) administered as a 1 hour IV infusion, once weekly for 3 weeks, followed by a 1-week rest until disease progression or unacceptable toxicity.
Study: 23530663
Drug: Ganetespib (STA-9090)
Normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganetespib (STA-9090) at doses escalating from 7 to 259 mg/m(2).
Study: 23530663
Drug: Ganetespib (STA-9090)
Normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganetespib (STA-9090) at 200 mg/m(2) given IV at Days 1, 8, and 15 every 4 weeks.
Study: 23530817
Drug: Morisky Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morisky Medication Adherence Scale (MMAS-4)
Study: 23530817
Drug: Treatment strategies
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment strategies and associated healthcare costs
Study: 23531361
Drug: NaHCO3 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaHCO3 (0.3 g·kg-1 body mass)
Study: 23531361
Drug: Placebo (0.045
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.045 g·kg-1 body mass NaCl)
Study: 23535095
Drug: Oral desensitization
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral desensitization protocol (200 mL)
Study: 23535095
Drug: Oral desensitization
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral desensitization protocol
Study: 23535954
Drug: Ipilimumab 10
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 10 mg/kg + radiotherapy (8 Gy/lesion)
Study: 23535954
Drug: Ipilimumab 10
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 10 mg/kg - Monotherapy
Study: 23537041
Drug: Lixisenatide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide (10 weeks treatment after ischemia-reperfusion)
Study: 23537041
Drug: Lixisenatide (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide (acute treatment during ischemia-reperfusion)
Study: 23537041
Drug: Lixisenatide (chronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide (chronic treatment)
Study: 23537121
Drug: Full-mouth scaling
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-mouth scaling and root planing (SRP) and systemic antibiotics
Study: 23537365
Drug: Low-dose LPS
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose LPS inhalation (2 μg)
Study: 23537365
Drug: Roflumilast treatment
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Roflumilast treatment (5 days) before last LPS challenge
Study: 23537966
Drug: Bendavia at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bendavia at 0.05 mg/kg per hour
Study: 23537966
Drug: Placebo (identically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identically appearing) administered as an intravenous infusion at 60 mL/h
Study: 23537968
Drug: Pharmacomechanical catheter-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacomechanical catheter-directed thrombolysis (PCDT) + standard therapy
Study: 23537968
Drug: PCDT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCDT + standard therapy
Study: 23538866
Drug: First-line chemotherapy
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line chemotherapy (CT)
Study: 23539736
Drug: 1-hour OGTT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-hour OGTT glucose of >155 mg/dL
Study: 23541126
Drug: Venlafaxine ER
Normalized name: Venlafaxine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine ER (37.5-225 mg/d)
Study: 23541189
Drug: Lurasidone (40-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lurasidone (40-120 mg/d)
Study: 23541189
Drug: Olanzapine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (15 mg)
Study: 23542823
Drug: Fecal microbial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbial transplantation (FMT) - freshly prepared fecal enemas daily for 5 days
Study: 23543609
Drug: Triazoles (62.7%)
Normalized name: Triazolam
DrugBank: Triazolam (DB00897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triazoles (62.7%) and echinocandins (34.2%) were the most commonly used antifungal agents; first-line therapy was typically fluconazole (37.7%).
Study: 23543609
Drug: First-line antifungal
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line antifungal susceptibility.
Study: 23543609
Drug: Treatment initiated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment initiated after diagnostic confirmation in 166/268 (61.9%) patients.
Study: 23543660
Drug: Teriparatide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teriparatide (20 μg daily for 18 to 24 months)
Study: 23547218
Drug: Rituximab (RTX)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (RTX) 2 × 500 mg added to current biologic and nonbiologic DMARD treatment
Study: 23547558
Drug: OM-174 (600,
Approvals — FDA: no, EMA: no, PMDA: no
Description: OM-174 (600, 800, or 1000 μg/m²) administered as intravenous infusion, twice weekly for a total of 5, 10, or 15 injections.
Study: 23547655
Drug: Nilotinib (average
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nilotinib (average daily dose of at least 720 mg)
Study: 23548165
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of [(14)C]pazopanib in suspension (400 mg, 70 µCi)
Study: 23548165
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 5 mg pazopanib followed by oral administration of 800 mg pazopanib tablet once daily for 26 days
Study: 23548728
Drug: Antithyroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithyroid therapy (ATT) for 4 months
Study: 23548879
Drug: Intravenous synthetic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous synthetic human secretin (sHS) 0.05-0.8 µg/kg for 3 days
Study: 23549489
Drug: In-hospital management
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-hospital management of patients on warfarin undergoing PCI-S
Study: 23549489
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (warfarin, aspirin, and clopidogrel) prescription at discharge
Study: 23551108
Drug: High-protein drink
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein drink (325 mL) with ice chips/water PRN
Study: 23551108
Drug: High-protein drink
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-protein drink (325 mL)
Study: 23551593
Drug: everolimus 10
Normalized name: everolimus 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: everolimus 10 mg orally once daily continuously (one cycle = 4 weeks)
Study: 23551918
Drug: rFVIIa administration
Normalized name: rFVIIa
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIIa administration for joint bleeds in children
Study: 23551918
Drug: rFVIIa administration
Normalized name: rFVIIa
DrugBank: Coagulation factor VIIa Recombinant Human (DB00036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIIa administration for joint bleeds in adults
Study: 23551933
Drug: 2009 trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2009 trivalent inactivated split-virion influenza vaccine (TIV) 0.25 ml (22.5 μg haemagglutinin) or 0.5 ml (45 μg) depending on age and prior vaccination history
Study: 23552982
Drug: Neoadjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant treatment with grades III and IV toxic effects
Study: 23552982
Drug: Poor tolerance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Poor tolerance of neoadjuvant treatment
Study: 23553066
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oxaliplatin (100 mg/m2), docetaxel (35 mg/m2), and vandetanib (100 mg PO daily)
Study: 23553066
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oxaliplatin (80 mg/m2), docetaxel (30 mg/m2), and vandetanib (100 mg PO daily)
Study: 23553848
Drug: Cabozantinib 20
Normalized name: cabozantinib 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 20 mg daily
Study: 26762579
Drug: Cabozantinib 100
Normalized name: cabozantinib 100 MG Daily Dose Carton
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 100 mg daily
Study: 23554030
Drug: Vorinostat (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (300 mg/m²/day) and Temozolomide (150 mg/m²/day)
Study: 23557023
Drug: Budesonide/formoterol (Symbicort
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (Symbicort SMART(®), 160/4.5 μg) twice daily plus as needed
Study: 23557757
Drug: Metformin (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (1,500 mg/day) for 16 weeks
Study: 23557757
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-insulin-resistant women), n = 5
Study: 23557865
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia with fentanyl
Study: 23557865
Drug: Genetic polymorphisms
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genetic polymorphisms (OPRM1 118A>G, ABCB1 2677G>A/T, ABCB1 3435C>T, CYP3A4*18, CYP3A5*3)
Study: 23558394
Drug: Citalopram (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20-40 mg/day) during level 1 treatment
Study: 23558394
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to sertraline, sustained-release bupropion, or extended-release venlafaxine or augmentation with sustained-release bupropion or buspirone during level 2 treatment
Study: 23558394
Drug: Initial treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial treatment responders
Study: 23558394
Drug: Second-step treatment
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Second-step treatment responders
Study: 23558394
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with treatment resistance
Study: 23559086
Drug: Oral macimorelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral macimorelin
Study: 23560574
Drug: NeuroBlate System
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeuroBlate System (laser interstitial thermal therapy)
Study: 23563210
Drug: Bevacizumab with
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab with chemotherapy (docetaxel, cyclophosphamide, followed by doxorubicin) every 3 weeks for 4 cycles, then surgery, followed by bevacizumab every 3 weeks for 9 cycles.
Study: 23564195
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy for CAP patients (mean duration = 11.1 days)
Study: 23564195
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy for AECOPD patients (mean duration = 8.9 days)
Study: 23565181
Drug: Rifaximin 550
Normalized name: rifAXIMin 550 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifaximin 550 mg BID for 8 weeks
Study: 23565931
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment for hyperglycaemia
Study: 23565931
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment for dyslipidaemia
Study: 23565931
Drug: Treatment targets
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment targets for haemoglobin A1c, LDL, HDL, non-HDL cholesterol, systolic BP, BMI, waist circumference
Study: 23566357
Drug: Minocycline (1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (1.4 mg/kg for six months)
Study: 23569312
Drug: PD0332991 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: PD0332991 200 mg orally once per day for 14 consecutive days in 21-day cycles
Study: 23569315
Drug: Trastuzumab (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab (4 mg/kg loading, then 2 mg/kg once per week) and lapatinib (1000 mg once per day for 12 weeks)
Study: 23569315
Drug: Trastuzumab and
Normalized name: pertuzumab and trastuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab and lapatinib with letrozole (plus LHRH agonist if premenopausal) for ER-positive tumors
Study: 23576625
Drug: CERE-120 (AAV2-neurturin)
Normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: CERE-120 (DB05637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CERE-120 (AAV2-neurturin) administered bilaterally to the substantia nigra and putamen
Study: 23577182
Drug: Mifepristone 200
Normalized name: mifepristone 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone 200 mg twice daily for 4 weeks
Study: 23581634
Drug: HuCNS-SC transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuCNS-SC transplantation (low-dose)
Study: 23581634
Drug: HuCNS-SC transplantation
Normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HuCNS-SC transplantation (high-dose)
Study: 23582881
Drug: Everolimus 10mg
Normalized name: EVEROLIMUS 10MG TAB
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus 10mg daily
Study: 23583440
Drug: Trametinib 2mg
Normalized name: TRAMETINIB 2MG ORAL TAB
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib 2mg daily with standard gemcitabine dosing (1000 mg/m(2) IV Days 1, 8, and 15 of 28-day cycles)
Study: 23583440
Drug: Standard gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard gemcitabine dosing (1000 mg/m(2) IV Days 1, 8, and 15 of 28-day cycles)
Study: 23584252
Drug: HZ/su vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: HZ/su vaccine (two doses according to a 0, 2-month schedule)
Study: 23586347
Drug: Initial antibiotic
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial antibiotic treatment modification
Study: 23586347
Drug: Streamlining (de-escalation)
Normalized name: sangre de grado
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streamlining (de-escalation) of therapy
Study: 23587148
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of adjuvant FOLFOX treatment
Study: 23588536
Drug: Pentostatin 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentostatin 1.5 mg/m(2)/day intravenously on days 1-3 of each 14-day cycle
Study: 23588536
Drug: Pentostatin 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentostatin 0.75 mg/m(2) after dose reduction
Study: 23588536
Drug: Pentostatin treatment
Normalized name: Pentostatin
DrugBank: Pentostatin (DB00552)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentostatin treatment
Study: 23589215
Drug: AZD8931 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8931 40 mg bid
Study: 23589215
Drug: AZD8931 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8931 80 mg bid
Study: 23589215
Drug: AZD8931 160
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8931 160 mg bid
Study: 23589215
Drug: AZD8931 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8931 240 mg bid
Study: 23589215
Drug: AZD8931 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8931 300 mg bid
Study: 23589215
Drug: AZD8931 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD8931 (all doses)
Study: 23589315
Drug: Cetuximab (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetuximab (initial dose of 400 mg/m(2) on day 1 followed by 250 mg/m(2) weekly)
Study: 23589410
Drug: Telehealth interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telehealth interventions for mental health treatment
Study: 23590701
Drug: PB 500
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB 500 mg twice daily with vitamin D3 5000 IU once daily (Group-II)
Study: 23590701
Drug: PB 250
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB 250 mg twice daily (Group-I)
Study: 23590701
Drug: PB 500
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB 500 mg twice daily (Group-I)
Study: 23590701
Drug: PB 500
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB 500 mg twice daily (Group-IV)
Study: 23590701
Drug: PB 500
Normalized name: PB-722
DrugBank: PB-722 (DB18447)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PB 500 mg twice daily (Group-I), PB 500 mg twice daily (Group-II), vitamin D3 5000 IU once daily (Group-V)
Study: 23591447
Drug: U3-1287 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: U3-1287 (20 mg/kg every 2 weeks)